References
1. Dome P, Rihmer Z, Gonda X. Suicide Risk in Bipolar Disorder: A Brief
Review. Medicina (Kaunas). 2019;55(8). 10.3390/medicina55080403
2. Muller MJ, Szegedi A. Effects of interrater reliability of
psychopathologic assessment on power and sample size calculations in
clinical trials. J Clin Psychopharmacol. 2002;22(3):318-325.
10.1097/00004714-200206000-00013
3. Kobak KA, Brown B, Sharp I, et al. Sources of unreliability in
depression ratings. J Clin Psychopharmacol. 2009;29(1):82-85.
10.1097/JCP.0b013e318192e4d7
4. Williams JB, Kobak KA. Development and reliability of a structured
interview guide for the Montgomery Asberg Depression Rating Scale
(SIGMA). Br J Psychiatry. 2008;192(1):52-58.
10.1192/bjp.bp.106.032532
5. Fassbender M. CRO Industry Still Plagued by Turnover: Report.
https://www.outsourcing-pharma.com/Article/2019/01/03/CRO-industry-still-plagued-by-CRA-turnover-Report.
6. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and Safety of
Lumateperone for Major Depressive Episodes Associated With Bipolar I or
Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.Am J Psychiatry. 2021;178(12):1098-1106.
10.1176/appi.ajp.2021.20091339
7. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and
olanzapine-fluoxetine combination in the treatment of bipolar I
depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
10.1001/archpsyc.60.11.1079
8. Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of
cariprazine in bipolar I depression: A double-blind, placebo-controlled
phase 3 study. Bipolar Disord. 2020;22(4):372-384.
10.1111/bdi.12852
9. Young AH, McElroy SL, Bauer M, et al. A double-blind,
placebo-controlled study of quetiapine and lithium monotherapy in adults
in the acute phase of bipolar depression (EMBOLDEN I). J Clin
Psychiatry. 2010;71(2):150-162. 10.4088/JCP.08m04995gre
10. Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with
lithium or valproate for bipolar depression: A placebo-controlled trial
utilizing prospective and retrospective enrolment cohorts. J
Psychiatr Res. 2016;78:86-93. 10.1016/j.jpsychires.2016.03.012
11. Iannuzzo RW, Jaeger J, Goldberg JF, Kafantaris V, Sublette ME.
Development and reliability of the HAM-D/MADRS interview: an integrated
depression symptom rating scale. Psychiatry Res.2006;145(1):21-37. 10.1016/j.psychres.2005.10.009
12. Mulsant BH, Kastango KB, Rosen J, Stone RA, Mazumdar S, Pollock BG.
Interrater reliability in clinical trials of depressive disorders.Am J Psychiatry. 2002;159(9):1598-1600.
10.1176/appi.ajp.159.9.1598
13. Liljequist D, Elfving B, Skavberg Roaldsen K. Intraclass correlation
- A discussion and demonstration of basic features. PLoS One.2019;14(7):e0219854. 10.1371/journal.pone.0219854
14. Targum SD, Catania CJ. Audio-digital recordings for surveillance in
clinical trials of major depressive disorder. Contemp Clin Trials
Commun. 2019;14:100317. 10.1016/j.conctc.2019.100317
15. Targum SD, Pendergrass JC, Toner C, Asgharnejad M, Burch DJ.
Audio-digital recordings used for independent confirmation of site-based
MADRS interview scores. Eur Neuropsychopharmacol.2014;24(11):1760-1766. 10.1016/j.euroneuro.2014.08.016
16. Targum SD, Daly E, Fedgchin M, Cooper K, Singh JB. Comparability of
blinded remote and site-based assessments of response to adjunctive
esketamine or placebo nasal spray in patients with treatment resistant
depression. J Psychiatr Res. 2019;111:68-73.
10.1016/j.jpsychires.2019.01.017